Early radiologic tumour volume response in non-metastatic rhabdomyosarcoma is not predictive for survival.

IF 2.3 3区医学 Q2 PEDIATRICS

Pediatric Radiology Pub Date : 2025-08-14 DOI:10.1007/s00247-025-06359-3

Isabelle S A de Vries, Carlo Morosi, Gianni Bisogno, Veronique Minard-Colin, Beatrice Coppadoro, Ilaria Zanetti, Andrea Ferrari, Daniel Orbach, Salma Moalla, Myriam Ben-Arush, Christine Devalck, Roelof van Ewijk, Kieran McHugh, Meriel Jenney, Julia Chisholm, Gabriela Guillen, Henry Mandeville, Johannes H M Merks, Rick R Van Rijn

{"title":"Early radiologic tumour volume response in non-metastatic rhabdomyosarcoma is not predictive for survival.","authors":"Isabelle S A de Vries, Carlo Morosi, Gianni Bisogno, Veronique Minard-Colin, Beatrice Coppadoro, Ilaria Zanetti, Andrea Ferrari, Daniel Orbach, Salma Moalla, Myriam Ben-Arush, Christine Devalck, Roelof van Ewijk, Kieran McHugh, Meriel Jenney, Julia Chisholm, Gabriela Guillen, Henry Mandeville, Johannes H M Merks, Rick R Van Rijn","doi":"10.1007/s00247-025-06359-3","DOIUrl":null,"url":null,"abstract":"Background: There is an urgent need for early radiological markers predicting survival in paediatric rhabdomyosarcoma patients.Objective: To analyse the predictive value of early radiological tumour volume response to chemotherapy in non-metastatic rhabdomyosarcoma patients.Methods: The European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study prospectively included non-metastatic rhabdomyosarcoma patients. Patients with Intergroup Rhabdomyosarcoma Studies (IRS) postsurgical Group III (i.e. measurable disease) at diagnosis, with three tumour diameters available at diagnosis and following three cycles of chemotherapy, were included. Tumour response was categorized as complete response, partial response, minor partial response, stable disease, or progressive disease. Patients with progressive disease were excluded from analyses. Failure-free survival and overall survival were estimated with Kaplan-Meier using a landmark analysis. Prognostic factors were assessed using Cox proportional hazards analyses.Results: Of 1,674 patients aged < 18 years at diagnosis included in the EpSSG RMS 2005 study, 613 patients (median age 4.2 years, interquartile range 2.2-8.0, 346 males) were eligible for analysis. After three cycles of chemotherapy, 48 patients reached complete response, 371 partial response, 139 minor partial response, 48 stable disease, and seven patients progressive disease. Univariate Cox proportional hazards model showed no significant difference between response groups for failure-free survival or overall survival. In multivariate Cox regression analysis, tumour volume response was not an independent prognostic factor for failure-free survival or overall survival.Conclusion: Early radiological tumour volume response after the third cycle of neoadjuvant chemotherapy, with exclusion of progressive disease, does not predict survival in paediatric rhabdomyosarcoma patients.","PeriodicalId":19755,"journal":{"name":"Pediatric Radiology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00247-025-06359-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There is an urgent need for early radiological markers predicting survival in paediatric rhabdomyosarcoma patients.

Objective: To analyse the predictive value of early radiological tumour volume response to chemotherapy in non-metastatic rhabdomyosarcoma patients.

Methods: The European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study prospectively included non-metastatic rhabdomyosarcoma patients. Patients with Intergroup Rhabdomyosarcoma Studies (IRS) postsurgical Group III (i.e. measurable disease) at diagnosis, with three tumour diameters available at diagnosis and following three cycles of chemotherapy, were included. Tumour response was categorized as complete response, partial response, minor partial response, stable disease, or progressive disease. Patients with progressive disease were excluded from analyses. Failure-free survival and overall survival were estimated with Kaplan-Meier using a landmark analysis. Prognostic factors were assessed using Cox proportional hazards analyses.

Results: Of 1,674 patients aged < 18 years at diagnosis included in the EpSSG RMS 2005 study, 613 patients (median age 4.2 years, interquartile range 2.2-8.0, 346 males) were eligible for analysis. After three cycles of chemotherapy, 48 patients reached complete response, 371 partial response, 139 minor partial response, 48 stable disease, and seven patients progressive disease. Univariate Cox proportional hazards model showed no significant difference between response groups for failure-free survival or overall survival. In multivariate Cox regression analysis, tumour volume response was not an independent prognostic factor for failure-free survival or overall survival.

Conclusion: Early radiological tumour volume response after the third cycle of neoadjuvant chemotherapy, with exclusion of progressive disease, does not predict survival in paediatric rhabdomyosarcoma patients.

查看原文本刊更多论文

非转移性横纹肌肉瘤的早期放射学肿瘤体积反应不能预测生存率。

背景：迫切需要早期放射学标志物来预测小儿横纹肌肉瘤患者的生存。目的：分析非转移性横纹肌肉瘤患者早期放射学肿瘤体积对化疗反应的预测价值。方法：欧洲儿科软组织肉瘤研究组（EpSSG） RMS 2005研究前瞻性纳入非转移性横纹肌肉瘤患者。患者组间横纹肌肉瘤研究（IRS）术后III组（即可测量的疾病）在诊断时有三个肿瘤直径，并经过三个周期的化疗。肿瘤反应分为完全反应、部分反应、轻微部分反应、病情稳定或病情进展。疾病进展的患者被排除在分析之外。无故障生存期和总生存期采用Kaplan-Meier里程碑分析进行估计。采用Cox比例风险分析评估预后因素。结论：在排除疾病进展的情况下，第三周期新辅助化疗后的早期放射学肿瘤体积反应不能预测小儿横纹肌肉瘤患者的生存。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Radiology 医学-核医学

CiteScore

4.40

自引率

17.40%

发文量

300

审稿时长

3-6 weeks

期刊介绍： Official Journal of the European Society of Pediatric Radiology, the Society for Pediatric Radiology and the Asian and Oceanic Society for Pediatric Radiology Pediatric Radiology informs its readers of new findings and progress in all areas of pediatric imaging and in related fields. This is achieved by a blend of original papers, complemented by reviews that set out the present state of knowledge in a particular area of the specialty or summarize specific topics in which discussion has led to clear conclusions. Advances in technology, methodology, apparatus and auxiliary equipment are presented, and modifications of standard techniques are described. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.